Publications by authors named "Per Arkhammar"

Claim this Profile
L
Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study.
Edeltraut Garbe, Fabian Hoti, Tania Schink, Kristian Svendsen, Haydar Al-Eid, Per Arkhammar

Int J Chron Obstruct Pulmon Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial.
Steven R Lentz, Savita Rangarajan, Faraizah A Karim, Philip D Andersen, Per Arkhammar

Blood Coagul Fibrinolysis· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of recombinant activated factor VII in patients with acquired haemophilia.
Andreas Tiede, Kagehiro Amano, Alice Ma, Per Arkhammar, Soraya Benchikh El Fegoun

Blood Rev· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety update on the use of recombinant activated factor VII in approved indications.
Ellis J Neufeld, Claude Négrier, Per Arkhammar, Soraya Benchikh el Fegoun, Mette Duelund Simonsen

Blood Rev· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors.
Elena Santagostino, Miguel Escobar, Margareth Ozelo, Luigi Solimeno, Per Arkhammar

Blood Rev· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Possible role of an ischemic preconditioning-like response mechanism in K(ATP) channel opener-mediated protection against streptozotocin-induced suppression of rat pancreatic islet function.
Stellan Sandler, Annika K Andersson, Jenny Larsson, Natalia Makeeva, Therese Olsen, Per O G Arkhammar

Biochem Pharmacol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
Flemming E Nielsen, Søren Ebdrup, Anette Frost Jensen, Lars Ynddal, Thora B Bodvarsdottir, Per O G Arkhammar

J Med Chem· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Akt pathway inhibitors using redistribution screening on the FLIPR and the IN Cell 3000 analyzer.
Betina Kerstin Lundholt, Viggo Linde, Frosty Loechel, Hans-Christian Pedersen, Søren Møller, Per O G Arkhammar

J Biomol Screen· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and pharmacological evaluation of 4H-1,4-benzothiazine-2-carbonitrile 1,1-dioxide and N-(2-cyanomethylsulfonylphenyl)acylamide derivatives as potential activators of ATP sensitive potassium channels.
Søren C Schou, Holger C Hansen, Tina M Tagmose, Harrie C M Boonen, Anne Worsaae, Per O G Arkhammar

Bioorg Med Chem· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-(4-Methoxyphenoxy)-5-nitro-N-(4-sulfamoylphenyl)benzamide activates Kir6.2/SUR1 K(ATP) channels.
Flemming E Nielsen, Palle Jacobsen, Anne Worsaae, Per O G Arkhammar, Philip Wahl

Bioorg Med Chem Lett· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment and application of in vitro membrane potential assays in cell lines with endogenous or recombinant expression of ATP-sensitive potassium channels (Kir6.2/SUR1) using a fluorescent probe kit.
Per Arkhammar, Philip Wahl, Berit Gerlach, Tinna Fremming, John B Hansen

J Biomol Screen· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets.
Kathrin Maedler, Joachim Størling, Jeppe Sturis, Richard A Zuellig, Giatgen A Spinas, Per O G Arkhammar

Diabetes· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arylcyanoguanidines as activators of Kir6.2/SUR1K ATP channels and inhibitors of insulin release.
Tina M Tagmose, Søren C Schou, John P Mogensen, Flemming E Nielsen, Per O G Arkhammar

J Med Chem· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders.
J Bondo Hansen, Per O G Arkhammar, Thora B Bodvarsdottir, Philip Wahl

Curr Med Chem· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dihydroxyacetone-induced oscillations in cytoplasmic free Ca2+ and the ATP/ADP ratio in pancreatic beta-cells at substimulatory glucose.
Lisa Juntti-Berggren, Dominic-Luc Webb, Per O G Arkhammar, Vera Schultz, Elke K H Schweda

J Biol Chem· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
6
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
Flemming E Nielsen, Thora B Bodvarsdottir, Anne Worsaae, Peter MacKay, Carsten E Stidsen, Per O G Arkhammar

J Med Chem· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis